Piperidinyl-3-(aryloxy)propanamides Modulate SSTR4 Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and other CNS disorders associated with somatostatin receptor 4 (SSTR4) lack effective pharmacological agents that can modulate SSTR4 activity to inhibit neuronal hyperactivity and improve cognitive functions.
Innovation Solution
Development of piperidinyl-3-(aryloxy)propanamide and propanoate derivatives that act as modulators of SSTR4, these compounds are designed to be used in pharmaceutical compositions for treating diseases, disorders, and conditions associated with SSTR4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then existing therapeutic options are available, but they lack effective pharmacological agents that can modulate SSTR4 activity
Solution Approach 1:
The patent applies parameter changes by developing a series of chemical compounds with varying molecular structures (Formula 1 with different substituents R1-R16, X1-X4, L, r, s) to optimize SSTR4 modulation. The systematic variation of chemical parameters allows tuning of receptor binding affinity and functional activity, directly addressing the need for effective SSTR4-modulating agents in Alzheimer's treatment
2Ease of operation
If SSTR4 agonists are developed to inhibit neuronal hyperactivity, then cognitive functions may be improved, but the complexity of identifying effective compounds increases
Solution Approach 1:
The patent segments the SSTR4 agonist development process into systematic chemical series (Formula 1 with defined variable positions X1-X4, R1-R16, L, r, s). This segmentation allows focused synthesis and testing of specific structural variants, reducing the overall complexity of identifying effective compounds by breaking down the problem into manageable chemical series
Solution Approach 2:
The patent creates a universal chemical scaffold (Formula 1) that can generate multiple SSTR4-modulating compounds with different pharmacological properties. This multi-functional platform allows a single core structure to explore various therapeutic possibilities, reducing complexity by providing a unified approach rather than developing entirely separate compound classes
Data Source
AI summary
Disclosed are compounds of Formula 1,stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.